Extracorporeal shockwave therapy for Peyronie's disease - guidance (IPG29)

National Institute for Health and Care Excellence - NICE
Publication date:
17 December 2003


The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on extracorporeal shockwave therapy for Peyronie's disease.

As part of NICE's work programme, the current guidance was considered for review but did not meet the review criteria as set out in the IP process guide. The guidance below therefore remains current.


The procedure involves the use of shockwave lithotripsy technology to treat Peyronie's disease.

Extracorporeal shockwaves are high pressure, low frequency sound waves, generated by a device outside the body and applied to the affected tissue in a site-specific manner. In Peyronie's disease, the penile plaque is the target of these shockwaves and is generally localised using a ultrasound scanner.

Shockwaves per session range from 2000–3000, with the average patient receiving around 3-5 treatment sessions.

Coding and clinical classification codes for this guidance.